Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma.

Lazzari E, Mondala PK, Santos ND, Miller AC, Pineda G, Jiang Q, Leu H, Ali SA, Ganesan AP, Wu CN, Costello C, Minden M, Chiaramonte R, Stewart AK, Crews LA, Jamieson CHM.

Nat Commun. 2017 Dec 4;8(1):1922. doi: 10.1038/s41467-017-01890-w.

2.

RNA editing-dependent epitranscriptome diversity in cancer stem cells.

Jiang Q, Crews LA, Holm F, Jamieson CHM.

Nat Rev Cancer. 2017 Jun;17(6):381-392. doi: 10.1038/nrc.2017.23. Epub 2017 Apr 18. Review.

3.

RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML.

Crews LA, Balaian L, Delos Santos NP, Leu HS, Court AC, Lazzari E, Sadarangani A, Zipeto MA, La Clair JJ, Villa R, Kulidjian A, Storb R, Morris SR, Ball ED, Burkart MD, Jamieson CHM.

Cell Stem Cell. 2016 Nov 3;19(5):599-612. doi: 10.1016/j.stem.2016.08.003. Epub 2016 Aug 25.

4.

Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.

Colombo M, Galletti S, Bulfamante G, Falleni M, Tosi D, Todoerti K, Lazzari E, Crews LA, Jamieson CH, Ravaioli S, Baccianti F, Garavelli S, Platonova N, Neri A, Chiaramonte R.

Oncotarget. 2016 Aug 30;7(35):56013-56029. doi: 10.18632/oncotarget.10820.

5.

ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis.

Zipeto MA, Court AC, Sadarangani A, Delos Santos NP, Balaian L, Chun HJ, Pineda G, Morris SR, Mason CN, Geron I, Barrett C, Goff DJ, Wall R, Pellecchia M, Minden M, Frazer KA, Marra MA, Crews LA, Jiang Q, Jamieson CHM.

Cell Stem Cell. 2016 Aug 4;19(2):177-191. doi: 10.1016/j.stem.2016.05.004. Epub 2016 Jun 9.

6.

An RNA editing fingerprint of cancer stem cell reprogramming.

Crews LA, Jiang Q, Zipeto MA, Lazzari E, Court AC, Ali S, Barrett CL, Frazer KA, Jamieson CH.

J Transl Med. 2015 Feb 12;13:52. doi: 10.1186/s12967-014-0370-3.

7.

Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disorders.

Fields JA, Dumaop W, Crews L, Adame A, Spencer B, Metcalf J, He J, Rockenstein E, Masliah E.

Curr HIV Res. 2015;13(1):43-54. Review.

8.

Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.

Wrasidlo W, Crews LA, Tsigelny IF, Stocking E, Kouznetsova VL, Price D, Paulino A, Gonzales T, Overk CR, Patrick C, Rockenstein E, Masliah E.

Br J Pharmacol. 2014 Dec;171(24):5757-73. doi: 10.1111/bph.12875.

9.

Clinical features, intestinal histopathology, and outcome in protein-losing enteropathy in Yorkshire Terrier dogs.

Simmerson SM, Armstrong PJ, Wünschmann A, Jessen CR, Crews LJ, Washabau RJ.

J Vet Intern Med. 2014 Mar-Apr;28(2):331-7. doi: 10.1111/jvim.12291. Epub 2014 Jan 27.

10.

Risk factors for coughing in dogs with naturally acquired myxomatous mitral valve disease.

Ferasin L, Crews L, Biller DS, Lamb KE, Borgarelli M.

J Vet Intern Med. 2013 Mar-Apr;27(2):286-92. doi: 10.1111/jvim.12039. Epub 2013 Feb 9.

11.

Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications.

Sullivan BD, Crews LA, Messmer EM, Foulks GN, Nichols KK, Baenninger P, Geerling G, Figueiredo F, Lemp MA.

Acta Ophthalmol. 2014 Mar;92(2):161-6. doi: 10.1111/aos.12012. Epub 2012 Dec 28.

12.

ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia.

Jiang Q, Crews LA, Barrett CL, Chun HJ, Court AC, Isquith JM, Zipeto MA, Goff DJ, Minden M, Sadarangani A, Rusert JM, Dao KH, Morris SR, Goldstein LS, Marra MA, Frazer KA, Jamieson CH.

Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):1041-6. doi: 10.1073/pnas.1213021110. Epub 2012 Dec 28.

13.

Selective elimination of leukemia stem cells: hitting a moving target.

Crews LA, Jamieson CH.

Cancer Lett. 2013 Sep 10;338(1):15-22. doi: 10.1016/j.canlet.2012.08.006. Epub 2012 Aug 17. Review.

PMID:
22906415
14.

α-Synuclein induces alterations in adult neurogenesis in Parkinson disease models via p53-mediated repression of Notch1.

Desplats P, Spencer B, Crews L, Pathel P, Morvinski-Friedmann D, Kosberg K, Roberts S, Patrick C, Winner B, Winkler J, Masliah E.

J Biol Chem. 2012 Sep 14;287(38):31691-702. doi: 10.1074/jbc.M112.354522. Epub 2012 Jul 25.

15.

NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches.

Ma W, Gutierrez A, Goff DJ, Geron I, Sadarangani A, Jamieson CA, Court AC, Shih AY, Jiang Q, Wu CC, Li K, Smith KM, Crews LA, Gibson NW, Deichaite I, Morris SR, Wei P, Carson DA, Look AT, Jamieson CH.

PLoS One. 2012;7(6):e39725. doi: 10.1371/journal.pone.0039725. Epub 2012 Jun 29.

16.

Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management.

Sullivan BD, Crews LA, Sönmez B, de la Paz MF, Comert E, Charoenrook V, de Araujo AL, Pepose JS, Berg MS, Kosheleff VP, Lemp MA.

Cornea. 2012 Sep;31(9):1000-8. doi: 10.1097/ICO.0b013e318242fd60.

PMID:
22475641
17.

Chronic myeloid leukemia stem cell biology.

Crews LA, Jamieson CH.

Curr Hematol Malig Rep. 2012 Jun;7(2):125-32. doi: 10.1007/s11899-012-0121-6.

18.

Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study.

Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD.

Cornea. 2012 May;31(5):472-8. doi: 10.1097/ICO.0b013e318225415a.

PMID:
22378109
19.

Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation.

Tsigelny IF, Sharikov Y, Wrasidlo W, Gonzalez T, Desplats PA, Crews L, Spencer B, Masliah E.

FEBS J. 2012 Mar;279(6):1000-13. doi: 10.1111/j.1742-4658.2012.08489.x. Epub 2012 Feb 27.

20.

Phosphorylation of collapsin response mediator protein-2 disrupts neuronal maturation in a model of adult neurogenesis: Implications for neurodegenerative disorders.

Crews L, Ruf R, Patrick C, Dumaop W, Trejo-Morales M, Achim CL, Rockenstein E, Masliah E.

Mol Neurodegener. 2011 Sep 24;6:67. doi: 10.1186/1750-1326-6-67.

21.

Regional comparison of the neurogenic effects of CNTF-derived peptides and cerebrolysin in AβPP transgenic mice.

Rockenstein E, Ubhi K, Doppler E, Novak P, Moessler H, Li B, Blanchard J, Grundke-Iqbal I, Iqbal K, Mante M, Adame A, Crews L, Masliah E.

J Alzheimers Dis. 2011;27(4):743-52. doi: 10.3233/JAD-2011-110914.

22.

Neurotoxic effects of the HCV core protein are mediated by sustained activation of ERK via TLR2 signaling.

Paulino AD, Ubhi K, Rockenstein E, Adame A, Crews L, Letendre S, Ellis R, Everall IP, Grant I, Masliah E.

J Neurovirol. 2011 Aug;17(4):327-40. doi: 10.1007/s13365-011-0039-0. Epub 2011 Jun 10.

23.

Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease.

Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L, Buttini M, Games D, Schenk D.

PLoS One. 2011 Apr 29;6(4):e19338. doi: 10.1371/journal.pone.0019338.

24.

Increased CDK5 expression in HIV encephalitis contributes to neurodegeneration via tau phosphorylation and is reversed with Roscovitine.

Patrick C, Crews L, Desplats P, Dumaop W, Rockenstein E, Achim CL, Everall IP, Masliah E.

Am J Pathol. 2011 Apr;178(4):1646-61. doi: 10.1016/j.ajpath.2010.12.033.

25.

Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer's disease.

Crews L, Patrick C, Adame A, Rockenstein E, Masliah E.

Cell Death Dis. 2011 Feb 10;2:e120. doi: 10.1038/cddis.2011.2.

26.

Intraosseous maxillary hemangioma in an immature Bassett Hound.

Hansen D, Goldstein G, Crews L, Snyder L, Speltz MC.

J Vet Dent. 2010 Winter;27(4):234-41.

PMID:
21322431
27.

Increased BMP6 levels in the brains of Alzheimer's disease patients and APP transgenic mice are accompanied by impaired neurogenesis.

Crews L, Adame A, Patrick C, Delaney A, Pham E, Rockenstein E, Hansen L, Masliah E.

J Neurosci. 2010 Sep 15;30(37):12252-62. doi: 10.1523/JNEUROSCI.1305-10.2010.

28.

Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins.

Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A, Salmon D, Galasko D, Michael S, Savas JN, Yates JR, Glabe C, Masliah E.

FEBS J. 2010 Jul;277(14):3051-67. doi: 10.1111/j.1742-4658.2010.07719.x. Epub 2010 Jun 22.

29.

Prevalence of incomplete ossification of the humeral condyle in the limb opposite humeral condylar fracture: 14 dogs.

Martin RB, Crews L, Saveraid T, Conzemius MG.

Vet Comp Orthop Traumatol. 2010;23(3):168-72. doi: 10.3415/VCOT-09-08-0082. Epub 2010 Apr 26.

PMID:
20422122
30.

Molecular mechanisms of neurodegeneration in Alzheimer's disease.

Crews L, Masliah E.

Hum Mol Genet. 2010 Apr 15;19(R1):R12-20. doi: 10.1093/hmg/ddq160. Epub 2010 Apr 22. Review.

31.

Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy.

Crews L, Spencer B, Desplats P, Patrick C, Paulino A, Rockenstein E, Hansen L, Adame A, Galasko D, Masliah E.

PLoS One. 2010 Feb 19;5(2):e9313. doi: 10.1371/journal.pone.0009313.

32.

APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis.

Crews L, Rockenstein E, Masliah E.

Brain Struct Funct. 2010 Mar;214(2-3):111-26. doi: 10.1007/s00429-009-0232-6. Epub 2009 Nov 29. Review.

33.

Age at diagnosis of autism spectrum disorders in four regions of Canada.

Ouellette-Kuntz HM, Coo H, Lam M, Yu CT, Breitenbach MM, Hennessey PE, Holden JJ, Brown HK, Noonan AL, Gauthier RB, Crews LR.

Can J Public Health. 2009 Jul-Aug;100(4):268-73.

PMID:
19722339
34.

Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein.

Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13010-5. doi: 10.1073/pnas.0903691106. Epub 2009 Jul 27. Erratum in: Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17606.

35.

Role of synucleins in Alzheimer's disease.

Crews L, Tsigelny I, Hashimoto M, Masliah E.

Neurotox Res. 2009 Oct;16(3):306-17. doi: 10.1007/s12640-009-9073-6. Epub 2009 Jun 24.

36.

Molecular pathology of neuro-AIDS (CNS-HIV).

Crews L, Patrick C, Achim CL, Everall IP, Masliah E.

Int J Mol Sci. 2009 Mar;10(3):1045-63. doi: 10.3390/ijms10031045. Epub 2009 Mar 11. Review.

37.

Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin.

Ubhi K, Rockenstein E, Doppler E, Mante M, Adame A, Patrick C, Trejo M, Crews L, Paulino A, Moessler H, Masliah E.

Acta Neuropathol. 2009 Jun;117(6):699-712. doi: 10.1007/s00401-009-0505-4. Epub 2009 Feb 28.

38.

Clinical, ultrasonographic, and laboratory findings associated with gallbladder disease and rupture in dogs: 45 cases (1997-2007).

Crews LJ, Feeney DA, Jessen CR, Rose ND, Matise I.

J Am Vet Med Assoc. 2009 Feb 1;234(3):359-66. doi: 10.2460/javma.234.3.359.

PMID:
19210257
39.

Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease.

Rose JB, Crews L, Rockenstein E, Adame A, Mante M, Hersh LB, Gage FH, Spencer B, Potkar R, Marr RA, Masliah E.

J Neurosci. 2009 Jan 28;29(4):1115-25. doi: 10.1523/JNEUROSCI.4220-08.2009.

40.

Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson's disease by disturbing calcium flux.

Marongiu R, Spencer B, Crews L, Adame A, Patrick C, Trejo M, Dallapiccola B, Valente EM, Masliah E.

J Neurochem. 2009 Mar;108(6):1561-74. doi: 10.1111/j.1471-4159.2009.05932.x. Epub 2009 Jan 24.

41.

Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice.

Spencer B, Marr RA, Rockenstein E, Crews L, Adame A, Potkar R, Patrick C, Gage FH, Verma IM, Masliah E.

BMC Neurosci. 2008 Nov 12;9:109. doi: 10.1186/1471-2202-9-109.

42.

Neuronal injury in simian immunodeficiency virus and other animal models of neuroAIDS.

Crews L, Lentz MR, Gonzalez RG, Fox HS, Masliah E.

J Neurovirol. 2008 Aug;14(4):327-39. doi: 10.1080/13550280802132840. Review.

43.

Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.

Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer B, Rockenstein E, Trejo M, Platoshyn O, Yuan JX, Masliah E.

PLoS One. 2008 Sep 4;3(9):e3135. doi: 10.1371/journal.pone.0003135.

44.

Biological transgenic mouse models of Alzheimer's disease.

Crews L, Rockenstein E, Masliah E.

Handb Clin Neurol. 2008;89:291-301. doi: 10.1016/S0072-9752(07)01227-4. Review. No abstract available.

PMID:
18631753
45.

Neurotrophic effects of Cerebrolysin in the Mecp2(308/Y) transgenic model of Rett syndrome.

Doppler E, Rockenstein E, Ubhi K, Inglis C, Mante M, Adame A, Crews L, Hitzl M, Moessler H, Masliah E.

Acta Neuropathol. 2008 Oct;116(4):425-37. doi: 10.1007/s00401-008-0407-x. Epub 2008 Jul 4.

46.

Alpha-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice.

Crews L, Mizuno H, Desplats P, Rockenstein E, Adame A, Patrick C, Winner B, Winkler J, Masliah E.

J Neurosci. 2008 Apr 16;28(16):4250-60. doi: 10.1523/JNEUROSCI.0066-08.2008.

47.

Utility of diagnostic tests for and medical treatment of pulmonary blastomycosis in dogs: 125 cases (1989-2006).

Crews LJ, Feeney DA, Jessen CR, Newman AB, Sharkey LC.

J Am Vet Med Assoc. 2008 Jan 15;232(2):222-7. doi: 10.2460/javma.232.2.222.

PMID:
18275389
48.

Radiographic findings in dogs with pulmonary blastomycosis: 125 cases (1989-2006).

Crews LJ, Feeney DA, Jessen CR, Newman AB.

J Am Vet Med Assoc. 2008 Jan 15;232(2):215-21. doi: 10.2460/javma.232.2.215.

PMID:
18275388
49.

Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease.

Bar-On P, Crews L, Koob AO, Mizuno H, Adame A, Spencer B, Masliah E.

J Neurochem. 2008 Jun;105(5):1656-67. doi: 10.1111/j.1471-4159.2008.05254.x. Epub 2008 Jan 28.

50.

alpha-Synuclein aggregates interfere with Parkin solubility and distribution: role in the pathogenesis of Parkinson disease.

Kawahara K, Hashimoto M, Bar-On P, Ho GJ, Crews L, Mizuno H, Rockenstein E, Imam SZ, Masliah E.

J Biol Chem. 2008 Mar 14;283(11):6979-87. doi: 10.1074/jbc.M710418200. Epub 2008 Jan 14.

Supplemental Content

Support Center